Loading stock data…
$17.83-0.80 (-4.29%)
Apnimed, Inc.
| Metric (USD) | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Total Revenue | $12.08M↓ | $84.81M↑ | $17.11M↑ | $3.13M |
| Gross Profit | $10.87M↓ | $82.65M↑ | $15.39M↑ | $1.81M |
| Operating Income | -$11.70M↓ | $68.04M↑ | -$5.94M↑ | -$27.11M |
| Net Income | $125.94M↑ | $70.37M↑ | -$69.47M↓ | -$28.65M |
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat ob...